Compile Data Set for Download or QSAR
maximum 50k data
Report error Found 1987 with Last Name = 'watts' and Initial = 'jp'
TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM100291(US8501744, 7)
Affinity DataKi:  0.350nMAssay Description:In vitro cathepsin inhibition assay.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin S(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103367(US8552202, Example 4)
Affinity DataKi:  0.400nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM100304(US8501744, 29)
Affinity DataKi:  0.400nMAssay Description:In vitro cathepsin inhibition assay.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM100305(US8501744, 30)
Affinity DataKi:  0.450nMAssay Description:In vitro cathepsin inhibition assay.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM100296(US8501744, 17)
Affinity DataKi:  0.450nMAssay Description:In vitro cathepsin inhibition assay.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM100295(US8501744, 22)
Affinity DataKi:  0.600nMAssay Description:In vitro cathepsin inhibition assay.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM100294(US8501744, 16)
Affinity DataKi:  0.700nMAssay Description:In vitro cathepsin inhibition assay.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM100297(US8501744, 18)
Affinity DataKi:  0.700nMAssay Description:In vitro cathepsin inhibition assay.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM100289(US8501744, 5)
Affinity DataKi:  0.75nMAssay Description:In vitro cathepsin inhibition assay.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM100300(US8501744, 25)
Affinity DataKi:  0.800nMAssay Description:In vitro cathepsin inhibition assay.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM100293(US8501744, 12)
Affinity DataKi:  0.800nMAssay Description:In vitro cathepsin inhibition assay.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM100301(US8501744, 26)
Affinity DataKi:  0.800nMAssay Description:In vitro cathepsin inhibition assay.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM100288(US8501744, 4)
Affinity DataKi:  1nMAssay Description:In vitro cathepsin inhibition assay.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM100290(US8501744, 6)
Affinity DataKi:  1.10nMAssay Description:In vitro cathepsin inhibition assay.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM100302(US8501744, 27)
Affinity DataKi:  1.20nMAssay Description:In vitro cathepsin inhibition assay.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM100287(US8501744, 2)
Affinity DataKi:  1.5nMAssay Description:In vitro cathepsin inhibition assay.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM100303(US8501744, 28)
Affinity DataKi:  1.5nMAssay Description:In vitro cathepsin inhibition assay.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM100292(US8501744, 8)
Affinity DataKi:  1.70nMAssay Description:In vitro cathepsin inhibition assay.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin S(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103364(US8552202, Compound 13)
Affinity DataKi:  1.70nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin S(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103361(US8552202, Example 2)
Affinity DataKi:  2.20nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM100286(US8501744, 1)
Affinity DataKi:  2.5nMAssay Description:In vitro cathepsin inhibition assay.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM100299(US8501744, 24)
Affinity DataKi:  3.20nMAssay Description:In vitro cathepsin inhibition assay.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin S(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103358(US8552202, Compound 9)
Affinity DataKi:  3.60nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM100298(US8501744, 23)
Affinity DataKi:  4.40nMAssay Description:In vitro cathepsin inhibition assay.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin S(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103354(US8552202, Example 1)
Affinity DataKi:  5nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM395229(US10308628, Compound 1)
Affinity DataKi:  7nMAssay Description:15 μL of [125I]CGP 42112A, at a final concentration of 0.05 nM was added to wells of assay plate.Membranes were dispersed using a 21 gauge needl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetCathepsin S(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103351(US8552202, Compound 3)
Affinity DataKi:  8.5nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM100285(CAC1 proteinases 5,5 bicyclic inhibitor 10)
Affinity DataKi:  8.70nMAssay Description:In vitro cathepsin inhibition assay.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM395233(US10308628, Compound 5)
Affinity DataKi:  9nMAssay Description:15 μL of [125I]CGP 42112A, at a final concentration of 0.05 nM was added to wells of assay plate.Membranes were dispersed using a 21 gauge needl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM395230(US10308628, Compound 2)
Affinity DataKi:  9nMAssay Description:15 μL of [125I]CGP 42112A, at a final concentration of 0.05 nM was added to wells of assay plate.Membranes were dispersed using a 21 gauge needl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetCathepsin S(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103363(US8552202, Example 3)
Affinity DataKi:  12nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM395232(US10308628, Compound 4)
Affinity DataKi:  15nMAssay Description:15 μL of [125I]CGP 42112A, at a final concentration of 0.05 nM was added to wells of assay plate.Membranes were dispersed using a 21 gauge needl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetCathepsin S(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103366(US8552202, Compound 15)
Affinity DataKi:  15nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM395231(US10308628, Compound 3)
Affinity DataKi:  17nMAssay Description:15 μL of [125I]CGP 42112A, at a final concentration of 0.05 nM was added to wells of assay plate.Membranes were dispersed using a 21 gauge needl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM395238(US10308628, Compound 10)
Affinity DataKi:  21nMAssay Description:15 μL of [125I]CGP 42112A, at a final concentration of 0.05 nM was added to wells of assay plate.Membranes were dispersed using a 21 gauge needl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM395237(US10308628, Compound 9)
Affinity DataKi:  23nMAssay Description:15 μL of [125I]CGP 42112A, at a final concentration of 0.05 nM was added to wells of assay plate.Membranes were dispersed using a 21 gauge needl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103364(US8552202, Compound 13)
Affinity DataKi:  23nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin S(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103360(US8552202, Compound 11)
Affinity DataKi:  24nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM395234(US10308628, Compound 6)
Affinity DataKi:  26nMAssay Description:15 μL of [125I]CGP 42112A, at a final concentration of 0.05 nM was added to wells of assay plate.Membranes were dispersed using a 21 gauge needl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103358(US8552202, Compound 9)
Affinity DataKi:  27nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin S(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103353(US8552202, Compound 5)
Affinity DataKi:  28nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM395236(US10308628, Compound 8)
Affinity DataKi:  30nMAssay Description:15 μL of [125I]CGP 42112A, at a final concentration of 0.05 nM was added to wells of assay plate.Membranes were dispersed using a 21 gauge needl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetCathepsin S(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103365(US8552202, Compound 14)
Affinity DataKi:  32nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin K(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103351(US8552202, Compound 3)
Affinity DataKi:  35nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin S(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103357(US8552202, Compound 8)
Affinity DataKi:  50nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM395235(US10308628, Compound 7)
Affinity DataKi:  50nMAssay Description:15 μL of [125I]CGP 42112A, at a final concentration of 0.05 nM was added to wells of assay plate.Membranes were dispersed using a 21 gauge needl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetCathepsin S(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103362(US8552202, Compound 12)
Affinity DataKi:  55nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin S(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103350(US8552202, Compound 2)
Affinity DataKi:  59nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin S(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103352(US8552202, Compound 4)
Affinity DataKi:  72nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetCathepsin S(Human)
Amura Therapeutics

US Patent
LigandPNGBDBM103355(US8552202, Compound 6)
Affinity DataKi:  75nMAssay Description:In vitro inhibition assay using cathepsin.More data for this Ligand-Target Pair
In DepthDetails US Patent

Displayed 1 to 50 (of 1987 total ) | Next | Last >>
Jump to: